000134915 001__ 134915 000134915 005__ 20250908131428.0 000134915 0247_ $$2doi$$a10.1515/almed-2024-0038 000134915 0248_ $$2sideral$$a138453 000134915 037__ $$aART-2024-138453 000134915 041__ $$aeng 000134915 100__ $$aPadilla Apuntate, Nuria 000134915 245__ $$aEffects of antidiabetic drugs on bone metabolism 000134915 260__ $$c2024 000134915 5060_ $$aAccess copy available to the general public$$fUnrestricted 000134915 5203_ $$aObjectives : The prevalence of diabetes mellitus type 2 (DMT2) is increasing exponentially worldwide. DMT2 patients have been found to be at a higher risk for bone fractures than the healthy population. Hence, improving our understanding of the impact of antidiabetic drugs on bone metabolism is crucial. Methods : A descriptive, retrospective study involving 106 patients receiving six groups of antidiabetic drugs: insulin; dipeptidylpeptidase four inhibitors (DPP4i); glucagon-like peptide type 1 receptor agonists (GLP1ra); sulfonylureas; sodium-glucose cotransporter two inhibitors (SGLT2i); and pioglitazone, in which osteocalcin (OC), bone alkaline phosphatase (BAP) and C-terminal telopeptide of collagen type 1 or beta-crosslaps (β-CTx) were determined. Results: β-CTx concentrations were higher in the patients treated with pioglitazone, as compared to patients treated with DPP4i (p=0.035), SGLT2i (p=0.020) or GLP1ra (p<0.001). The lowest β-CTx concentrations were observed in the patients treated with GLP1ra. Conclusions: Bone remodeling is influenced by the type of antidiabetic drug administered to DMT2 patients. In our study, the patients who received pioglitazone showed higher β-CTx concentrations, as compared to patients treated with other types of antidiabetic drugs. This finding highlights the convenience of avoiding these drugs, especially in postmenopausal women with DMT2. GLP1ra drugs were associated with the lowest β-CTx concentrations, which suggests that these agents could exert beneficial effects on bone metabolism 000134915 540__ $$9info:eu-repo/semantics/openAccess$$aby$$uhttp://creativecommons.org/licenses/by/3.0/es/ 000134915 592__ $$a0.254$$b2024 000134915 593__ $$aMedical Laboratory Technology$$c2024$$dQ2 000134915 593__ $$aMedicine (miscellaneous)$$c2024$$dQ3 000134915 593__ $$aEducation$$c2024$$dQ3 000134915 655_4 $$ainfo:eu-repo/semantics/article$$vinfo:eu-repo/semantics/publishedVersion 000134915 700__ $$aPuerto Cabeza, Carmen G. 000134915 700__ $$aGallego Royo, Alba$$uUniversidad de Zaragoza 000134915 700__ $$aGoñi Ros, Nuria 000134915 700__ $$aAbadía Molina, Claudia 000134915 700__ $$0(orcid)0000-0002-2987-6351$$aAcha Pérez, Javier 000134915 700__ $$aCalmarza, Pilar 000134915 7102_ $$11007$$2610$$aUniversidad de Zaragoza$$bDpto. Medicina, Psiqu. y Derm.$$cArea Medicina 000134915 773__ $$g5, 1 (2024), 85-89$$pAdv. lab. med$$tAdvances in laboratory medicine$$x2628-491X 000134915 8564_ $$s378158$$uhttps://zaguan.unizar.es/record/134915/files/texto_completo.pdf$$yVersión publicada 000134915 8564_ $$s2958140$$uhttps://zaguan.unizar.es/record/134915/files/texto_completo.jpg?subformat=icon$$xicon$$yVersión publicada 000134915 909CO $$ooai:zaguan.unizar.es:134915$$particulos$$pdriver 000134915 951__ $$a2025-09-08-12:55:10 000134915 980__ $$aARTICLE